Abeona shares tumble as FDA declines to approve skin disorder treatment
Abeona Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) had declined to approve its treatment for a rare skin blistering condition, sending its shares down 51% in after-market trading.